BTIG maintains Cartesian stock Buy rating, $42 target

BTIG reaffirmed a Buy rating on Cartesian Therapeutics (RNAC) with a $42 price target, citing the enrollment of the first patient in the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis and durable efficacy data from the Phase 2b study. Analysts highlight Descartes-08's tolerability and differentiation from DNA-based CAR-T therapies, while Cantor Fitzgerald and H.C. Wainwright maintain positive outlooks with price targets of $22 and $40, respectively; upcoming data for systemic lupus erythematosus in 2025 could further validate the therapy's potential.

Analysis

Cartesian Therapeutics (RNAC) is advancing its lead candidate, Descartes-08, with the recent initiation of patient enrollment in the Phase 3 AURORA trial for myasthenia gravis (MG), a key development underscored by BTIG's reaffirmed Buy rating and $42.00 price target. This progress builds on Phase 2b data that demonstrated exceptional durability and a favorable safety profile, notably differentiating Descartes-08 from DNA-based CAR-T therapies by avoiding common adverse events like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and not increasing hypogammaglobulinemia risk. Despite a significant 68% stock price decline over the past year to its current $9.63, resulting in a market capitalization of approximately $250 million, analyst sentiment, including positive ratings from Cantor Fitzgerald ($22 PT) and H.C. Wainwright ($40 PT), remains optimistic, with InvestingPro also suggesting potential undervaluation. The AURORA trial incorporates design elements, such as enrolling acetylcholine receptor antibody-positive patients and a longer treatment duration, aimed at potentially enhancing efficacy. The company reported last twelve months revenue of $34.17 million. A crucial future catalyst is the anticipated data for Descartes-08 in systemic lupus erythematosus (SLE) in the second half of 2025, which could establish its "pipeline-in-a-product" potential. Concurrently, the company announced its Chief Technology Officer, Dr. Metin Kurtoglu, will transition to a consulting role effective May 1, 2025.

Key Decisions for Investors

• Investors should evaluate the considerable upside potential suggested by analyst price targets, such as BTIG's $42.00, against the current share price of $9.63, while factoring in the stock's historical volatility and the inherent risks associated with clinical-stage biotechnology companies.
• Closely monitor progress and data readouts from the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis, as well as the anticipated data for systemic lupus erythematosus in H2 2025, as these are pivotal catalysts that could significantly influence RNAC's valuation.
• Consider the upcoming transition of the Chief Technology Officer to a consulting role in May 2025, noting that current analyst sentiment remains broadly supportive despite this leadership change.